Life Science Investing Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® Over Five Years 3h
Life Science Investing CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering 27 October
Life Science Investing Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines 21 October
